Last updated: September 8, 2026
Privigen is CSL Behring’s 10% intravenous immune globulin, or IVIG, used for primary immunodeficiency, immune thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy. Its commercial trajectory is supported by recurring demand, limited plasma supply, complex manufacturing and broad reimbursement. Product-level revenue is not publicly disclosed, so Privigen’s financial performance must be assessed through CSL Behring’s immunoglobulin franchise, company filings and market conditions.
Privigen does not have a conventional small-molecule patent-expiry event that would automatically trigger generic substitution. Competitive pressure is more likely to arise from other plasma-derived IVIG products, contracting, supply availability, hospital formularies and the launch of biosimilar or follow-on immunoglobulin products.
What is Privigen and how does it generate revenue?
Privigen is a sterile, preservative-free, 10% human normal immunoglobulin solution administered intravenously. CSL Behring manufactures and markets the product in multiple jurisdictions. The active substance consists of pooled human IgG collected from donated plasma and purified through a multistep manufacturing process.[1]
The product is used in three principal U.S. indications:
| Indication |
Commercial role |
| Primary immunodeficiency |
Recurring replacement therapy and relatively predictable demand |
| Chronic immune thrombocytopenic purpura |
Intermittent immunomodulatory treatment |
| Chronic inflammatory demyelinating polyneuropathy |
Recurring maintenance therapy with significant dosing volume |
The FDA approved Privigen in 2008 for primary immunodeficiency. The label was later expanded to include ITP and CIDP.[1] Treatment is generally administered by specialty pharmacies, hospital outpatient departments, infusion centers or physician offices.
Privigen revenue is generated through a combination of product volume, treatment duration, payer mix and price. Demand is less sensitive to ordinary economic cycles than demand for elective medicines, but utilization can be affected by reimbursement restrictions, hospital budgets and product allocation.
How large is the Privigen and IVIG market?
The global immunoglobulin market is one of the largest plasma-derived pharmaceutical markets. IVIG accounts for a substantial share of demand because it is used across immunology, hematology, neurology, rheumatology and infectious-disease settings.
The main structural growth drivers are:
- Expanded diagnosis of primary immunodeficiency.
- Increased use of IVIG in CIDP and other neurologic disorders.
- Greater diagnosis and treatment of secondary immunodeficiency.
- Aging populations with higher prevalence of immune and inflammatory conditions.
- Expanded treatment in emerging markets.
- Greater clinical acceptance of immunoglobulin therapy in selected off-label settings.
The main constraints are plasma availability, donor recruitment, collection-center capacity, manufacturing lead times and reimbursement. Immunoglobulin manufacturing requires large plasma volumes. A supply disruption cannot be corrected quickly because collection, testing, fractionation, purification and batch release occur over extended cycles.
The COVID-19 pandemic demonstrated the supply sensitivity of the category. Plasma collection declined during the early pandemic, while demand remained strong. Manufacturers subsequently expanded collection capacity and adjusted donor compensation and recruitment strategies. Supply has improved, but the market remains exposed to donor participation and regulatory restrictions affecting plasma collection.
What companies compete with Privigen?
Privigen competes primarily with other IVIG and subcutaneous immunoglobulin products rather than with conventional generic drugs.
| Product |
Company |
Type |
Competitive relevance |
| Privigen |
CSL Behring |
10% IVIG |
Broad indication base and established hospital presence |
| Hizentra |
CSL Behring |
Subcutaneous immunoglobulin |
Internal substitute for selected maintenance patients |
| Gamunex-C |
Grifols |
10% IVIG |
Major U.S. IVIG competitor |
| Gammagard Liquid |
Takeda |
10% IVIG |
Broad immunology and neurology presence |
| Octagam 10% |
Octapharma |
10% IVIG |
Competes in hospital and specialty channels |
| Panzyga |
Octapharma |
10% IVIG |
Newer IVIG competitor in the U.S. |
| Flebogamma DIF |
Grifols |
IVIG |
International and U.S. competitive presence |
| Asceniv |
ADMA Biologics |
IVIG |
U.S. product focused on primary immunodeficiency |
Competition is based on supply reliability, infusion tolerability, adverse-event profile, formulation, contract pricing, distribution reach and physician familiarity. Because products are biologically derived and manufacturing processes differ, automatic pharmacy substitution is less common than in conventional generic markets.
How has CSL Behring’s financial trajectory affected Privigen?
CSL Behring does not report Privigen as a standalone revenue line. CSL typically reports performance at the Behring segment level and discusses immunoglobulin demand, pricing, volumes and plasma costs without separately identifying Privigen revenue.[2]
The financial trajectory has therefore been driven by four variables:
- Immunoglobulin volume growth.
- Pricing and product mix.
- Plasma collection costs.
- Manufacturing capacity and supply utilization.
CSL’s Behring business has benefited from strong demand for immunoglobulins, specialty plasma products and treatments for bleeding disorders. Immunoglobulin demand has supported the segment, while higher plasma collection and operating costs have pressured margins during periods of supply tightness.[2]
Privigen is strategically valuable because it produces recurring sales from chronic replacement and maintenance indications. Its mature status limits the probability of rapid price increases, but the product’s established use and manufacturing scale support long-term commercial durability.
What revenue exposure does Privigen represent?
Privigen’s exact revenue exposure is not disclosed by CSL. Any estimate based on total Behring revenue would overstate precision because the segment includes products such as Hizentra, Idelvion, Berinert, Haegarda, albumin and other plasma-derived or recombinant therapies.
The most defensible financial conclusion is that Privigen is a material contributor to CSL Behring’s immunoglobulin franchise, but its standalone sales, margin and geographic revenue mix are not publicly reported.
What is the FDA regulatory status of Privigen?
Privigen is licensed in the United States under biologics license application 125127. The FDA-approved U.S. label identifies the product as immune globulin intravenous, human, 10% liquid.[1]
Key regulatory characteristics include:
| Regulatory issue |
Privigen status |
| Product class |
Plasma-derived biologic |
| U.S. pathway |
Biologics license application |
| U.S. approval |
2008 |
| Primary U.S. indications |
PI, ITP and CIDP |
| Dosage form |
Intravenous liquid |
| Strength |
10% IgG |
| Substitution framework |
Not equivalent to ordinary AB-rated generic substitution |
| Safety monitoring |
Infusion reactions, thrombosis, renal risk and hemolysis among labeled concerns |
The product label requires attention to infusion rate, renal function, thrombosis risk and patient-specific tolerability. These factors can influence product selection and switching decisions.
What patents and exclusivity protect Privigen?
Privigen’s commercial protection is not defined by a single highly visible composition-of-matter patent. The product is a mature plasma-derived biologic, and its competitive protection is distributed across regulatory approval, manufacturing know-how, process controls, quality systems, trademarks, supply infrastructure and commercial relationships.
Does Privigen have Orange Book protection?
The Orange Book primarily lists approved drug products and patent information for conventional pharmaceutical applications. Privigen is licensed as a biologic under a BLA, so the relevant regulatory framework is the Public Health Service Act and the FDA’s biologics systems rather than ordinary Hatch-Waxman generic substitution.[3]
The Purple Book provides biologic reference-product and biosimilar information. Privigen’s competitive position should therefore be assessed through BLA status, reference-product rules, biosimilar filings and manufacturing barriers rather than an Orange Book patent table.[4]
What formulation patents protect Privigen?
Public commercial disclosures do not establish a single current formulation patent that independently controls the market for all 10% IVIG products. Formulation and process know-how can still protect:
- Stabilizer composition.
- Protein concentration and pH control.
- Virus inactivation and removal.
- Aggregation control.
- Storage stability.
- Container and fill-finish specifications.
- Lot-release testing and quality attributes.
These protections are difficult for competitors to replicate quickly because regulatory approval requires demonstration of consistent manufacturing and product quality.
When does Privigen lose exclusivity?
Privigen does not have a conventional publicly stated small-molecule patent cliff. The economic loss of exclusivity is more likely to occur gradually through competing IVIG products, payer pressure or a future biosimilar or follow-on immunoglobulin approval.
Biologics licensed under the modern U.S. framework receive reference-product exclusivity periods, but the practical timing of competition depends on the product’s approval history and the applicable statutory transition rules.[3] Privigen’s 2008 approval predates the current biosimilar market and does not create a simple patent-expiration date comparable to a tablet drug.
The commercial risk profile is therefore:
| Risk |
Timing profile |
Expected effect |
| Direct generic substitution |
Low under ordinary generic rules |
Limited automatic erosion |
| Competing IVIG products |
Ongoing |
Contract and formulary pressure |
| Biosimilar or follow-on IVIG |
Medium term, regulatory dependent |
Potential price and share erosion |
| Plasma shortage |
Cyclical |
Can restrict volume but support pricing |
| Manufacturing failure |
Event-driven |
Could cause allocation and reputational damage |
| Internal substitution to Hizentra |
Ongoing |
May shift revenue within CSL’s portfolio |
Are there Paragraph IV challenges or Privigen patent lawsuits?
No major publicly established Paragraph IV litigation event defines Privigen’s current market position. Paragraph IV litigation is a Hatch-Waxman mechanism for small-molecule drugs and does not map directly onto a mature BLA product such as Privigen.
The relevant litigation risks are more likely to involve:
- Patent disputes over immunoglobulin manufacturing methods.
- Biosimilar approval challenges.
- Trade-secret claims involving plasma fractionation.
- Product liability and adverse-event litigation.
- Contract disputes over supply and distribution.
- Regulatory challenges involving interchangeability or labeling.
Without a confirmed litigation record tied specifically to Privigen, the commercial assessment should not assume a near-term court-driven launch event.
What manufacturing and intellectual-property barriers protect Privigen?
The strongest barriers are operational rather than purely patent-based.
Plasma supply
CSL operates a large plasma collection network and has invested heavily in collection centers, donor recruitment and testing. A new entrant needs access to substantial plasma volumes before it can compete at scale.
Fractionation technology
Manufacturing requires validated processes for plasma pooling, IgG purification, viral inactivation, viral removal and impurity control. Process changes can trigger regulatory review and comparability requirements.
Quality and consistency
IVIG products must maintain consistent potency, purity, stability and tolerability. Batch variability and immunoglobulin aggregation are important technical risks.
Distribution
Hospital and specialty-pharmacy customers value reliable allocation. A product with lower nominal price may not displace an incumbent if supply continuity is uncertain.
How does Privigen compare with subcutaneous immunoglobulin products?
Subcutaneous products such as Hizentra compete with IVIG in selected maintenance settings. They can reduce infusion-center dependence and allow home administration. IVIG remains important where rapid immunomodulation, high-dose therapy or established hospital protocols are preferred.
| Factor |
Privigen IVIG |
Subcutaneous immunoglobulin |
| Administration |
Intravenous infusion |
Home or clinic injection |
| Typical use |
Replacement and high-dose immunomodulation |
Maintenance replacement or selected chronic therapy |
| Site of care |
Hospital, infusion center or office |
Increasingly home-based |
| Operational burden |
Infusion appointments and monitoring |
Patient training and repeated administration |
| Competitive risk |
Faces other IVIG products |
Can shift patients away from IVIG |
CSL can retain some patients within its portfolio when treatment moves from Privigen to Hizentra. That reduces the company’s net exposure to external competition but may reduce reported Privigen volume.
What generic entry risks exist for Privigen?
The most credible entry scenario is not an immediate generic launch. It is gradual competition from another licensed immunoglobulin with comparable indications, followed by payer-driven contracting and selective switching.
Potential launch scenarios include:
- A competing IVIG gains approval for overlapping indications and competes on price.
- A biosimilar or follow-on product enters through the 351(k) pathway.
- A hospital system adopts a preferred IVIG supplier after a competitive tender.
- Supply shortages force temporary substitution between products.
- Subcutaneous immunoglobulin expands and reduces IVIG utilization in maintenance patients.
The risk of abrupt erosion is lower than for a conventional drug with an expired active-ingredient patent. The risk of gradual margin compression is higher.
What licensing deals affect Privigen?
Privigen is primarily an internally developed CSL Behring product. No major current licensing transaction is publicly identified as the central driver of its commercial position. The product’s economics depend more on CSL’s plasma collection, manufacturing and distribution infrastructure than on third-party licensing.
Key Takeaways
- Privigen is a mature 10% IVIG product marketed by CSL Behring.
- Its approved U.S. indications are primary immunodeficiency, ITP and CIDP.
- CSL does not disclose Privigen revenue separately.
- The product benefits from recurring demand and limited automatic substitution.
- Its principal competitive threats are other IVIG products, subcutaneous immunoglobulin and future biosimilar or follow-on products.
- Plasma availability, manufacturing scale and quality systems are stronger barriers than a single identifiable patent.
- Privigen has no conventional Orange Book patent cliff that establishes a clear generic-entry date.
- Paragraph IV litigation is not the primary exclusivity risk for this BLA product.
- Revenue durability is favorable, but price and margin pressure can increase as plasma supply improves and payers intensify contracting.
FAQs About Privigen Market Dynamics
Is Privigen interchangeable with Gamunex-C or Gammagard?
No automatic generic substitution should be assumed. Physicians and institutions may switch between IVIG products, but the products are biologically derived and may differ in formulation, stabilizers, indications, tolerability and administration protocols.
Is Privigen a biosimilar?
No. Privigen is the original CSL Behring IVIG product marketed under its own biologics license. A future biosimilar or follow-on product would require separate FDA approval.
Does Privigen have a patent expiration date?
There is no single publicly determinative patent-expiration date that functions as a conventional generic cliff for Privigen. Competition depends on biologic regulation, manufacturing capability, market access and product-specific intellectual property.
What is the main supply risk for Privigen?
The principal supply risk is insufficient plasma collection or a disruption in CSL’s fractionation and manufacturing network. Because plasma-derived products require long production cycles, supply cannot be expanded immediately.
Can Privigen sales grow after more than 15 years on the market?
Yes. Growth can come from increased diagnosis, broader use in CIDP and immunodeficiency, geographic expansion, higher treatment intensity and improved supply. Growth is more likely to be volume-driven than based on major new patent-protected pricing power.
References
- U.S. Food and Drug Administration. (2024). Privigen: Immune globulin intravenous (human), 10% liquid prescribing information. FDA.
- CSL Limited. (2024). Annual report 2024. CSL Limited.
- U.S. Food and Drug Administration. (2024). Approval pathways for biologics and biosimilars under the Public Health Service Act. FDA.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.
